Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Investor Presentation (September 2021)
25 slides from Diamedica Therapeutics's investor presentation, Sep 13, 2021
Slide 1: DiaMedica Investor Presentation September 2021
8% DiaMedica Zan TI y Investor Presentation September 2021
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the US. Private Securities Litigation Reform Act of 1995 and the words “estimate” “believe” ‘antcipate” “intend,” “expect.” “pan. neeatve ofthese words of compo trnaogy an
Slide 3: Potential New Standard of Care for Acute Ischemic Stroke (AIS)
Potential New Standard of Care for Acute Ischemic Stroke (AIS) Unique Opportunity to Strong Supporting 4 Recombinant KLK1 ‘Two Paths to Fast ‘Address AIS Market Data from Asia Product - DM199 Approval in Stroke c * Ku + Efficacy - : ir patient study, 90-day endpoint *+ Opportunity to address + Kuk .
Slide 4: Stroke Represents a Large, Underserved Market
Stroke Represents a Large, Underserved Market Gaps in Treatment Lead to Significant Disability and Stroke Recurrence Acute Ischemic Stroke (AIS) Blockage of 15 million 800,000 87% inbral year globally year in US ischemic in brain strokes bility >500,000: DM199 initial US target market >$10B estimate
Slide 5: 80% of Ischemic Stroke Patients Lack Treatment Options
80% of Ischemic Stroke Patients Lack Treatment Options DM199 Addresses This Gap by Expanding the Treatment Window to 24 Hours Post Stroke [siete | ossher | 457i | vation | when | ah | E ‘Small Vessel Occlusion (svo) Large Vessel ‘Occlusion (tvo) a _ 1 weatneivaces) 4 _Limtesto Lv strokes, 1 Uimtesto
Slide 6: DM199 Improves Endothelial Health
DM199 Improves Endothelial Health Differentiated Mechanism Addresses Both Recovery and Prevention of Recurrent Strokes Healthy blood vessels improve stroke recovery and reduce stroke reccurence. i DiaMeaica
Slide 7: Profound Treatment Effect in Stroke with Marketed Urinary KLK1 in Asia
Profound Treatment Effect in Stroke with Marketed Urinary KLK1 in Asia Improves Recovery and Reduces Risk for Recurrent Stroke Ore row Research Article thes ine: NEDICATREARCH ‘Tissue Kallikrein Activity, Detected by a Novel Method, meeitenee 200+ Urinary-KLK1 clinical studies demonstrated efficacy,
Slide 8: DM199 Prevented Ischemic Stroke Recurrences in Phase Trial
DM199 Prevented Ischemic Stroke Recurrences in Phase 2 Trial Even More Pronounced in Non-Mechanical Thrombectomy Participants Recurrent Ischemic Stroke at Day 90 ‘Cumulative incidence (%) OP eMedica All Participants Cumulative Incidence () Non-MT Participants. Neat “19% P0087 0.0% DMi99 N25
Slide 9: Improvement in Stroke Recovery and Lower Death Rate vs Placebo in Phase 2
Improvement in Stroke Recovery and Lower Death Rate vs Placebo in Phase 2 Potential to Increase Patients with Full or Nearly Full Recovery and to Resume Normal Lives Stroke Outcomes and Deaths at Day 90 Non-MT Participants Deaths NIHSS <1 mRS <1 . en = - & in comparison to placebo
Slide 10: Potential Benefit Much Greater Than Recently Approved Drug For Recurrence
Potential Benefit Much Greater Than Recently Approved Drug For Recurrence Modest Benefit by Brilinta® Led to Label Expansion in 2020 For Preventing Stroke Recurrence Recurrent Ischemic Stroke Absolute Risk Reduction Briuiyta. Mild Stroke Severity 52130 PdieMedica 2 woiestae awh ptes FeSO 0 dos Pane
Slide 11: DM199 Shows Improvement in Stroke Recovery
DM199 Shows p in Stroke Recovery All Studies Excluded MT Kaillkang® M199 inary KLEL Recombinant KLKA 1 New Een Jae od 199: 5581561 1588 and EN 2008S 25.391591517 2 edtedrth SBN bate ree nntacnlhonarhoge. Pa 3 35H pdiaMedica _} seinen te 9 Stroh t= eed ake mre intonooinemtoe ash ot 5 Dante tonne
Slide 12: DM199 Excellent Safety Profile
DM199 Excellent Safety Profile Consistent with Earlier DM199 Studies and Approved Human Urinary Forms of KLK1 + 250+ participants dosed with DM199 in studies including stroke, kidney disease and healthy volunteers © 2,000+ doses administered + No serious adverse events related to DM199 : inuations o
Slide 13: ReMEDy2 DM199 Pivotal P2/3 Trial Design Enables Two Shots on Goal
wy Be \s ReMEDy2 DM199 Pivotal P2/3 Trial Design Enables Two Shots on Goal ‘Two Independent Primary Endpoints with Interim Analysis: Stroke Recovery & Stroke Recurrence Key iy Ct ISS 5 to 20 - Recovery: Momence eS) . | eae ees + AIS confirmed via — aan = cama” Feat “panera ———— ; rea) (ee tenes eee
Slide 14: ReMEDy2 Successful if it Achieves ~Half of the Effect Observed in Phase 2
\sReMEDy2 Successful if it Achieves ~Half of the Effect Observed in Phase 2 Three potential labels with Recovery / Recurrence Potential Indication & Usage Label Pa £0.05 for both «| Seoke Recoven®: J+, Improve Stroke Recovery & Reduce Risk of Recurrence Stroke Recurrence: Vv = v - ns + Stroke Recove
Slide 15: DiaMedica Pipeline
DiaMedica Pipeline Focus on Pivotal Study in AIS and Completion of Phase 2 Kidney Studies Product | Precinical | Phase! Tiger eet ester 021 Binded FD ncn ia ana Lehnert onc EE renter a SE venta Recombinant protein OP eMedica
Slide 16: Pipeline: Future CKD opportunity
Pipeline: Future CKD opportunity
Slide 17: DM199 Mechanism Applies to Improving Kidney Health
DM199 Mechanism Applies to Improving Kidney Health KLK1 Is Predominately Produced in Kidneys & Regulates Multiple Interrelated Mechanisms efferent 19 Potential peri DM199 Potential Ce Regulate blood flow (1 ¢GFR): Improve micro vascularization bod flow Improve glomerular function (J. U @© © ketucena
Slide 18: DM199 for IgA Nephropathy and Hypertensive African Americans
DM199 for IgA Nephropathy and Hypertensive African Americans Areas for Potential Label Expansion After Stroke IgA Nephropathy Hypertensive African Americans with CKD Arare and devastating cause of kidney disease CGFB) with prevalence of 140K in Us, 200K in EU, SW ~6 million African Americans with CK
Slide 19: IgA Nephropathy - Interim Analysis REDUX Phase CKD, after 95 days Treatment
IgA Nephropathy - Interim Analysis REDUX Phase 2 CKD, after 95 days Treatment KOLs Excited By Significant Reductions Seen in Moderate/Severe Patients - Warrants Further Study UACR Change By Patient - Moderate to Severe Baseline Albuminuria (UACR >500) (N=11) % Change from Baseline & 8 z3 ' ' ' i ' f
Slide 20: Corporate Summary
Corporate Summary taMedica
Slide 21: DM199 Multi-layered IP Position
DM199 Multi-layered IP Position, ii for latory ivi Patents & Manufacturing & Regulatory Exclusivity Trade Secrets Patents Produced at up to 250L o eyed matter + Planned commercial scale. perereann * High-efficiency production based Reel eee for creating and growing cells that + Dosing, route of deli
Slide 22: Leadership Clinical Advisory Boards
Leadership Clinical Advisory Boards Stroke/C Rick Pauls MBA Philp Bath, M.D. OSC President & CEO Stoke Ase esd the De fest walt fNottrenan. Scott Kellen,CPA Scott Kasner, MD. 25+ years in fe scenes inst. CPA act el senor ud CFO are COO for sever phate and Peeeviann ple sdb compares Poofe Kha, MO. Jr
Slide 23: Stock and Financial Information
Stock and Financial Information <j DiaMedica NASDAQ (DMAC) Recent Price (September 1, 2021) Market Capitalization Shares Outstanding Fully Diluted Shares Outstanding Cash and Investments (June 30, 2021) Debt $4.30 $81M 19M 20.5M $21M $0
Slide 24: Summary
Summary Unique Opportunity to Address AIS Market & Strong Supporting Data from Asia 1 Recombinant KLK1 Product - DM199 ‘Two Paths to Fast Approval in Stroke KLK + Efficacy ~ ir patient study, 90-day endpoint + Opportunity to address KLKi : approval oF i approved to treat stroke patients endpoint: re
Slide 25: Thank you!
Thank you! NASDAQ: DMAC iv www.diamedica.com
DiaMedica Therapeutics — Investor Presentation (September 2021) on 6ix